Who is sponsoring NCT02112630?

NCT02112630 is sponsored by Columbia University.

What condition does NCT02112630 study?

NCT02112630 studies Hepatitis C Infection, End Stage Renal Disease.

What drugs are being tested in NCT02112630?

Interventions: P-IFN alfa 2a, P-IFN alfa 2b, Ribavirin, Boceprevir.

What is the status of NCT02112630?

NCT02112630 is currently WITHDRAWN.

Last reviewed 2015-09-21 · How we verify

Prospective, Single-Center, Open Label, Pilot Study of Safety and Efficacy of Triple Anti-Viral Therapy With Pegylated Interferon, Ribavirin, and Boceprevir in Patients With Genotype 1 Chronic HCV With End Stage Renal Disease

NCT02112630 NA WITHDRAWN

The purpose of the study is to assess the safety and efficacy of triple therapy with pegylated interferon (P-IFN), ribavirin and boceprevir in patients with genotype 1 chronic Hepatitis C Virus (HCV) infection and end stage renal disease (ESRD) on hemodialysis (HD).

Details

Lead sponsor	Columbia University
Phase	NA
Status	WITHDRAWN
Start date	2013-05
Completion	2015-02

Conditions

Hepatitis C Infection
End Stage Renal Disease

Interventions

P-IFN alfa 2a
P-IFN alfa 2b
Ribavirin
Boceprevir

Primary outcomes

Proportion of patients who achieve sustained virologic response — Up to 12 weeks after discontinuation of all therapy
Primary efficacy is the proportion of patients who achieve sustained virologic response at week 12 after discontinuation of all therapy (SVR12).